Prognostic Markers in the Treatment of Abiraterone Acetate + Prednisolone and Enzalutamide in Castration-Resistant Metastatic Prostate Cancer; Prognostic Value of Neutrophil Lymphocyte Ratio in Post - Docetaxel Setting

Abstract

Objectives: To evaluate the relationship between the neutrophil lymphocyte ratio (NLR) and progression-free survival (PFS) at the start of enzalutamide or abiraterone acetate treatment in metastatic castration-resistant prostate cancer (mCRPC) at post-docetaxel setting. Methods: Patients whom progressed after at least 6 cycles of docetaxel chemotherapy, included. Cases with